Conference corner: Cut through the sepsis confusion at the 2020 ACDIS conference
There’s a lot of talk about the transition from sepsis-2 to sepsis-3, but only one conference is bringing you the latest—straight from the source authority.
Attendees of the 13th annual ACDIS conference in their conference registration a pass to attend Sepsis transition update by Mitchell M. Levy, MD, a physician who played a principal role in pioneering both definitions.
Levy is chief, division of pulmonary, critical care, and sleep medicine, Department of Medicine, at The Warren Alpert Medical School of Brown University where he is a professor of medicine. He also serves as medical director of the medical intensive care unit (ICU) at Rhode Island Hospital. He has been an investigator on numerous pharmacologic and biologic trials intended to treat sepsis as well as cardiovascular and pulmonary pathology. Levy has expertise in trial design, clinical trial execution, and trial management, and is one of the three founding members of the Surviving Sepsis Campaign (SSC).
Levy is the past president of the Society of Critical Care Medicine (2009). His current research interests include implementation science in sepsis, clinical trials in sepsis, biomarkers, and end-of-life care in the ICU. He has authored more than 200 peer-reviewed articles and 25 book chapters. He is the co-director of the Ocean State Clinical Coordinating Center, which manages large, international, multi-center clinical trials in sepsis.
Levy is very active in the field of quality and safety, and has worked on several state-wide initiatives on quality, including New York, Rhode Island, Connecticut, Colorado, and New Jersey. He advises the New York Department of Health Sepsis Initiative and CMS SEP-1 Measure Program.
Register for the 2020 ACDIS national conference today and learn from the best on this challenging diagnosis.